Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV
1.3.2024 15:35:00 EET | Business Wire | Press release
The DRIPBaR, recognized as the fastest-growing IV therapy franchise in the United States, has joined forces with REVIV, the global leader in IV therapy, marking a significant milestone for the industry. The partnership creates an unrivaled offering by bringing together the specialties of two industry heavyweights boasting over 200 locations across 6 continents, with plans to add thousands more locations in the coming years. The recent surge in demand for IV therapy presents enormous opportunities globally for the companies to redefine industry standards and spearhead the next era of IV therapy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301173923/en/
Ben Crosbie, CEO of The DRIPBaR and Sarah Lomas, Founder and CEO of REVIV Global, announce their exciting partnership. (Photo: Business Wire)
With an extensive pipeline boasting over 450 franchisees in the United States, The DRIPBaR's decision to integrate REVIV's proprietary technology-backed proposition, REVIV X, validates their commitment to provide personalized and precision nutrition solutions for their customers. This partnership empowers The DRIPBaR to leverage REVIV's 10 years of intellectual property and life science expertise, utilizing objective data from blood tests and DNA analysis to tailor IV therapies to individual needs. Through REVIV X, The DRIPBaR is poised to revolutionize the wellness landscape in the United States, offering patient-focused solutions that optimize health outcomes that will solidify its position as a leader in innovation.
Ben Crosbie, CEO of The DRIPBaR, expressed excitement in the collaboration, affirming, "By selecting REVIV as our strategic partner, we are unlocking personalized and precision capabilities for a more advanced product offering and customer experience. I’m very confident that leveraging REVIV's cutting-edge technology and expertise will accelerate the growth of our franchisees and position them ahead of industry norms. The REVIV X proposition, coupled with its accredited IV Academy training course, sets a global benchmark for excellence in our field, empowering us to maintain industry leadership."
Sarah Lomas, Founder and CEO of REVIV Global, highlighted the transformative impact of the partnership, stating, "The DRIPBaR's alignment with REVIV underscores our joint dedication to innovation and safety in the IV therapy market. As industry leaders, we are reshaping the future of wellness by offering personalized and precision nutrition solutions that cater to evolving customer needs. We will continue to develop our SaaS products to power the industry globally. After many years and significant investment in research and product development, it’s exciting to see such early validation and adoption for REVIV X."
This strategic alliance between REVIV and The DRIPBaR marks a pivotal moment in the IV therapy industry and multi-modality sectors, advancing the delivery of safe, effective, and tailored wellness solutions to customers across the United States and beyond. As the IV therapy market continues its rapid expansion, with safety and compliance at the forefront, REVIV X emerges as the solution of choice for IV therapy operators, creating the opportunity for existing multi-modality businesses to access REVIV's innovative solutions and maintain their position at the forefront of wellness innovation and industry standards.
About REVIV Global
REVIV Global is at the forefront of advanced wellness solutions, devoted to enriching health and vitality through state-of-the-art IV therapy treatments. With a widespread international footprint and a relentless pursuit of innovation, REVIV is spearheading a revolution in the wellness sector. Its distinctive technological platform empowers IV therapy providers to deliver personalized and precision solutions with unparalleled safety and efficiency.
About The DRIPBaR
The DRIPBaR, a pioneering brand in the realm of wellness, is poised to redefine the landscape of health and vitality through advances in IV therapy. With cutting-edge science and a strong commitment to safety, The DRIPBaR offers a transformative approach to cellular health and personalized care. Focusing on ever-evolving treatments and medical advancements, The DRIPBaR embraces a new era of wellness where rejuvenation, vitality, and optimized health converge.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301173923/en/
Contact information
For media inquiries:
REVIV Global: Emma Robertson, erobertson@revivme.com
The DRIPBaR: Marketing@thedripbar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 18:51:00 EEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom